Analyst Price Targets — MOLN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| January 27, 2026 11:06 am | — | H.C. Wainwright | $13.00 | $4.00 | TheFly | Molecular Partners initiated with a Buy at H.C. Wainwright |
| April 27, 2022 6:21 am | — | Leerink Partners | $29.00 | $13.89 | Benzinga | SVB Leerink Maintains Outperform on Molecular Partners, Lowers Price Target to $29 |
Latest News for MOLN
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that Clare Fisher was elected by shareholders to its Board of…
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 23, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today published the invitation to the Annual General Meeting 2026 and announced the nomination of Clare Fisher for election as…
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will hold an oral presentation outlining new preclinical data on Radio-DARPins at the 3rd Global…
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced it will present three posters at the American Association for Cancer Research (AACR) 2026 Annual Meeting,…
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Zurich-Schlieren, Switzerland and Concord, Mass., March 12, 2026 – Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced…
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for MOLN.
Senate Trading
No Senate trades found for MOLN.
U.S. House Trading
No House trades found for MOLN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.